Abstract
Recently, a series of new approvals or expanded indications for small-molecule drugs indicated for acute myeloid leukemia (AML) has occurred. Small-molecule drugs greatly improve AML treatment options and contribute to prolonged prognosis; however, drug resistance is inevitable with long-term use. New modalities that have immune cell therapy should be developed using chimeric antigen receptor (CAR)-T cells which is one of the most promising next-generation cancer therapies for hematological cancers, and with awaited practical application in AML. Although CAR-T cell development that targets various AML-related antigens has progressed so far, products close to practical use have remained unavailable globally due to the AML-specific drug discovery challenges. This article will review the clinical development of CAR-T cells and discuss the developmental issues in AML from the viewpoint of target antigen characteristics and on-target/off-tumor toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: [Rinsho ketsueki] The Japanese journal of clinical hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
